Dr. Kaplan

Kaplan Publications by Decade

  • KAPLAN, H.G., Malmgren, J.A., Atwood, M, Goldstein, L.C.: “Positive Response to Neoadjuvant Cyclophosphamide and Doxorubicin in Topoisomerase II Non-Amplified/Her2/neu negative/Polysomy C17 Absent Breast Cancer Patients,” Cancer Mgmt & Res, 2:213-218; 2010.
  • KAPLAN, H.G., Malmgren, J.A., and Atwood, M.K.: “Increased Incidence of Myelodysplastic Syndrome and Acute Myeloid Leukemia Following Breast Cancer Treatment with Radiation Alone or In Combination with Chemotherapy: A Registry Cohort Analysis 1990-2005,” BMC Cancer 11:260; 2011
  • Malmgren, J.A., Atwood, M.K., and KAPLAN, H.G: “Breast Cancer Detection Method Among 20-49 Year Old Patients at a Community Based Cancer Center: 1990 – 2008,” Breast J 18:257-260; 2012.
  • Malmgren, J.A., Parik, J., Atwood, M.K., and KAPLAN, H.G.: “Impact of Mammography Detection on the Course of Breast Cancer in Women Age 40-49,” Radiology 262:797-806; 2012.
  • KAPLAN, H.G., and Malmgren, J.A.: “The Breast Cancer Overdiagnosis Conundrum,” Ann Int Med 158:60-62; 2013.
  • KAPLAN, H.G., Malmgren, J.A., and Atwood, M.K.: “Adjuvant Chemotherapy and Differential Invasive Breast Cancer Specific Survival in Elderly Women,” J Geriatric Onc 4:148-156;2013.
  • KAPLAN, H., Malmgren, J., and DeRoos, A.: “Risk of MDS/AML Post Radiation Treatment for Breast Cancer: Analysis of SEER Data 2001-2009,” Breast Ca Res Treat 137:863-867; 2013.
  • Yee, D., Haddad, T., Albain, K., Barker, A., Benz, C., Buxton, M., Chien, A., DeMichele, A., Dilts, D., Elias, A., Haluska, P., Hogarth, M., Hu, a., Hylton, N., KAPLAN, H., Kelloff, G., Khan, Q., lang, J., Leyland-Jones, B., Liu, M., Nanda, R., Northflet, D., Olopade, O., Park, J., Parker, B., Parkinson, D., Pearson-White, S., Pusztai, L., Symmans, F., Rugo, H., Tripathy, D., Wallace, A., Wholley, D., van ‘t Veer, L., Berry, D., and Esserman, L.: “Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development,” J Clin Oncol 30:4584-4586; 2013.
  • KAPLAN, H.G., Malmgren, J.A., Li, C., and Calip, G.S.: “Age Related Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia Among Invasive Breast Cancer Survivors: Analysis of SEER Data 2001-2009,” Breast Ca Res Treat 142:629-636; 2013.
  • KAPLAN, H.G.: “Vemurafenib Treatment of V600E-Mutated Malignant Peripheral Nerve Sheath Tumor,” J Natl Comp Can Net 11:1466-1470; 2013.
  • Nassiri, F., Scheithauer, B.W., Corwin, D.J., KAPLAN, H.G., Mayberg, M., Cusimano, M.D., Rotondo, F., and Kovacs, K.: “Invasive Thymoma Metastatic to the Cavernous Sinus,” Surg Neurol Int 4:74; 2013.
  • Ryu, R.J., Eyal, S., KAPLAN, H.G., Akbarzadeh, A., Hays, K., Puhl, K., Easterling, T.R., Berg, S.L., Scorsone, K.A., Feldman, E.M., Umans, J.G., Miodovnik, M., and Hebert, M.F.: “Pharmacokinetics of Doxorubicin in Pregnant Women,” Can Chemo Pharm 73(4): 789-797; 2014.
  • Malmgren, J.A., Parikh, J., Atwood, M.K., and KAPLAN, H.G.: “Improved Prognosis of Breast Cancer in Women Age 75 and Older with Mammography Detection,” Radiology 273:686-694; 2014.
  • de Vos, S., Forero-Torres, A., Ansell, S.M., Kahl, B., Cheson, B.D., Bartlett, N.L., Furman, R.R., Winter, J.N., KAPLAN, H., Timmerman, J., Whiting, N.C., Drachman, J.G., and Advani, R.: “A phase II study of dacetuzumab (SGN-40) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) and Correlative Analyses of Patient-Specific Factors,” J Hematol Onc 7:44-53; 2014.
  • DeMichele, A., Yee, D., Berry, D.A., Albain, K.S., Benz, C.C., Boughey, J., Buxton, M., Chia, S.K., Chien, A.J., Chui, S.Y., Clark, A., Edmiston, K., Elias, D.A., Forero-Torres, A., Haddad, T.C., Haley, B., Haluska, P., Hylton, N.M., Isaacs, C., KAPLAN, H., Korde, L., Leyland-Jones, B., Liu, M.C., Melisko, , M., Minton, S.E., Moulder, S., Nanda, R., Olopade, O.I., Paoloni, M., Park, J.W., Parker, B.A., Perlmutter, J., Petricoin, E.F., Rugo, H.S., Symmans, W.F., Tripathy, D., can’t Veer, L.J., Viscusi, R.K., Wallace, A., Wolf, D., Yau, C., and Esserman, L.J.: “The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer,” Clin Ca Res 29:2911-2915; 2015.
  • KAPLAN, H., Malmgren, J., Atwood, M., and Calip, G.: “Effect of Treatment and Mammography Detection on Breast Cancer Survival Over Time: 1990-2011,” Cancer 121:2553-61; 2015.
  • Leger, R., Jain, S., Nester, T., and KAPLAN, H.: “Drug-induced Immune Hemolytic Anemia Due to Anti-Carboplatin Plus the First Example of Anti-Paclitaxel,” Transfusion, 55:2949-2954; 2015.
  • Calip, G.S., Malmgren, J.A., Lee, W-J., Schwartz, S.M., and KAPLAN, H.G.: “Myelodysplastic Syndrome and Acute Myeloid Leukemia Following Breast Cancer Treatment Among Older Women: Analyses from the SEER-Medicare Database, 2001-2009”, Breast Can Res Treat 154:133-143; 2015.
  • Klempner, S.,J., Bordoni, R., Gowen, K., KAPLAN, H., Stephens, P.J., Ou, S.I., and Ali, S.M.: “Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF-Inhibitor Therapy,” JAMA Oncol 2(2):272-274; 2016.
  • Rugo, H.S., Olopade, O.I., DeMichele,A., Yau, C., van’t Veer, L.J., Buxton M.B., Hogarth, M., Hylton, N., Paoloni, M., Perlmutter, J., Symmans, W.F., Yee, D., Chien, A.J., Wallace, A.M., KAPLAN, H.G., Boughey, J.C., Haddad, T.C., Albain K.S., Liu, M.C., Isaacs, C., Khan, K.J., S.L., Lang, J., Viscusi, R.K.,Pusztai, L., Moulder, S.L., Chui, S.Y., Kemmer, K.A., Elias, A.D., Edmiston, K.K., Euhus, D., Haley, B.B., Nanda, R., Northfelt, D., Tripathy, D., Wood, W.C., Ewing, c., Schwab, R., Lyandres, J., Davis, S.E., Hirst, G.L., Sanil, A., Berry, D.A., and Esserman, L.J.: “First Results From the Phase 2, Adaptively Randomized, I-Spy 2 Trial for High Risk Early Breast Cancer: Efficacy of Veliparib plus Carboplatin When Added to Standard Neoadjuvant Chemotherapy,” New Eng J Med 375(1):23-34; 2016.
  • Park, J.W., Liu, M.C., Yee, D., Yau, C., van’t Veer, L.J., Symmans, W.F., Paoloni, M., Perlmutter, J., Hylton, N.M., Hogarth, M., DeMichele, A., Buxton, M.B., Chien, A.J., Wallace, A.M., Boughley, J.C., Haddad, T.C., Chui, S.Y., Kemmer, K.A., KAPLAN, H.G., Liu, M.C., Isaacs, C., Nanda, R., Tripathy, D., Albain, K.S., Edmiston, K.K., Elias, A.D., Northfelt, D.W., Pusztai, L., Moulder, S.L., Lang, J.E., Viscusi, R.K., Euhus, D.M., Haley, B.B., Khan, Q.J., Wood, Melisko, M., Schwab, R., Helsten, T., W.C., Lyandres, J., Davis, S.E., Hirst, G.L., Sanil, A., Esserman, L.J., and Berry, D.A: “Neratinib Plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the Phase 2 Randomized I-SPY 2 Trial,” New Eng J Med 375(1):11-22; 2016.
  • Malmgren, J.A., Calip, G.S., Atwood, M.K., and KAPLAN, H.G.: “Myelodysplastic Syndrome Following Primary Breast Cancer Treatment: Incidence, Treatment and outcomes From a Prospective Cohort Registry,” Leuk Res 47:178-184; 2016.
  • KAPLAN, H.G., Malmgren, J.A., and Atwood, M.K.: “Triple Negative Breast Cancer in the Elderly: Prognosis and Treatment,” The Breast J 23:630-637; 2017.
  • Malmgren, J.A., Mayer, M., Atwood, M.K., and KAPLAN, H.G.: “Differential Presentation and Prognosis of De Novo and Recurrent Metastatic Breast Cancer,” Breast Ca Res Treat 167:567-590; 2018.
  • KAPLAN, H.G., Rostad, S., Ross, V.A., Ali, S.M., and Millis, S.Z.:“Comprehensive Genomic Profiling in Patients with Malignant Peripheral Nerve Sheath Tumors Identifies BRAF Mutations, Revealing Routes to Potential New Treatment Options,” J Natl Comp Can Net, 16:967-974; 2018.
  • Kantrowitz-Gordon, I., Hays, K., Olumide, A.R.K., Easterling, T.R., KAPLAN, H.G., Reid, J.M., Safgren, S.L., Ames, M.M., and Hebert, M.F.: “Pharmacokinetics of Dacarbazine (DTIC) in Pregnancy,” Can Chemo Pharm 81:455-460; 2018.
  • Rivkin, S.E., Moo, >, Iriarte, D.S., Bailey, E., Sloan, H.L., Boatman, B., Goodman, G.E., BonDurant, A.E., Veljovich, D., Jiang, P., Wahl, T., Shah, C.A., Dresscher, A., KAPLAN, H.G., Peters, W.A., Ellis, E.D., Fer, M.F., Parl, M.F., Johnston, E., Summers, L., and Wiseman, C.: “Phase Ib wih Expansion Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients. NCT01650376,” Int J Gyn Onc, in press.
  • Boughey, J., Alvarado, M., Lancaster, R., Symmans, W., Mukhtar, R , Wong, J , Ewing, C., Potter, D., Tuttle, T., Hieken, T., Carter, J., Jakub, J., KAPLAN, H., Buchanan, C., Jaskowiak, N., Sattar, H., Mueller, J., Nanda, R., Isaacs,C., Pohlmann, P., Lynce, F., Tousimis, E., Zeck, J., Lee,M., Lang, J., Mhawech-Fauceglia, P., Rao, R., Taback, B., Chen, M., Kalinsky, K., Hibshoosh, H., Killelea, B. , Sanft, T., Hirst , G., Asare, S., Matthews, J., Perlmutter, J. , Esserman, L: “Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint,” npjBreast Cancer, in press.
  • Malmgren, J.A., Hurlbert, M., Atwood, M.K., and KAPLAN, H.G.: “Examination of a Paradox: Decline in Recurrent Metastatic Breast Cancer Incidence Over Time Without Improvement in Distant Disease Survival: 1990-2011,” submitted.
  • Jo Chien, A., Tripathy, D., Albain, K.S., Symmans, W.F., Rugo, H.S., Melisko, M.E., Wallace, A.M., Schwab, R., Helsten, T., Forero-Torres, A., Stringer-Reasor, E., Ellis, E.D., KAPLAN, H.G., Nanda, R., Jaskowiak, N., Murthy, R., Godellas, C., Boughey, J.C., Elias, A.D., Haley, B.B., Kemmer, K., Isaacs, C., Clark, A.S., Lang, J.E., Lu, J., Korde, L., Edmiston, K.K., Northfelt, D.W., Viscusi, R.K., Yee, D., Perlmutter, J., Hylton, N.M., van’t Veer, L.J., DeMichele, A., Wilson, A., Buxton, M.B., Mathews, J., Steeg, K., Singhrao, R., Hirst, G.K., Sanil, A., Yau, C., Asare, S.M., Berry,D., Esserman, L.D., on behalf of I-Spy 2 Consortium: “MK-2206 Combined with Paclitaxel-Based Neoadjuvant Therapy Improves Treatment Response and Long-Term Outcomes in Patients with Her2-Positive and/or HR-Negative Breast Cancers: Results from the I-SPY2 Trial,” submitted.
  • KAPLAN, H.G., Malmgren, J.A. and Calip G.S,: “Therapy-related Myelodysplastic Syndrome and AcuteMyeloid Leukemia: The Role of Granulocyte Colony-Stimulating Factors,” (letter) JAMA Oncol 5(7):1065; 2019.
  • KAPLAN, H.G., Malmgren, J.A. and Calip G.S.: “Therapy-related Myelodysplastic Syndrome/Acute Myelogenous Leukemia Rick Considerations in Current Breast Cancer Treatment,” submitted.
  • Malmgren, J.A., Calip, G.S., Atwood, M.K., Mayer, M. and KAPLAN, H.G.: “metastatic Breast Cancer Survival Improvement Restricted by regional Disparity SEER and Institutional Analysis: 1990-2011,” Cancer, in press.
  • KAPLAN, H.G., Malmgren, J.A., and Atwood, M.: “Leukemia Incidence Post Primary Breast Cancer Treatment,” Cancer 101:1529-1536; 2004.
  • KAPLAN, H.G., Malmgren, J.A., and Atwood, M.: “Impact of Detection Method on the Course of Breast Cancer: Patient versus Mammography Detected,” Clin. Breast Cancer, 7(2):133-140;2006.
  • KAPLAN, H.G., and Malmgren, J.A.: “Impact of Triple Negative Phenotype on Breast Cancer Prognosis,” Breast J 14(5):456-463; 2008.
  • Vemulakonda, V.M., Lendvay, T.S., Shnorhavorian, M., Joyner, B.D., KAPLAN, H., Mitchell, M.E., and Grady, R.W.: “Metastatic Adenocarcinoma after Augmentation Gastrocystoplasty, J Urology 179(3):1094-7; 2008.
  • Malmgren, J.A., Atwood, M., and KAPLAN, H.: “Increase in Mammography Detected Breast Cancer Over Time at a Community Based Regional Cancer Center: A Longitudinal Cohort Study, 1990 – 2005,” BMC Cancer 8:131-7; 2008.
  • Witzig, T.E., Wiernik, P.H., Moore, T., Reeder, C., Coe, C., Justice, G., KAPLAN, H., Voralia, M., Pietronigro, D., Takeshita, K., Ervin-Hayes, A., Zeldis, J.B., and Vose, J.M.: “Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma,” J Clin Onc, 27(32):5404-9; 2009.
  • KAPLAN, H.G., Malmgren, J.A., and Atwood, M.: “T1N0 Triple Negative Breast Cancer: Recurrence Risk and Adjuvant Chemotherapy,” Breast J 15(5):454-460; 2009
  • Navari, R.M., KAPLAN, H.G., Gralla, R.J., Grunberg, S.M., Palmer, R., and Fitts, D.: “Efficacy and Safety of Granisetron, A Selective 5-HT3 Antagonist, In the Prevention of Nausea and Vomiting Induced by High Dose Platinum,” J. Clin. Oncol. 12:2204; 1994.
  • Perez, E., Navari, R.M., KAPLAN, H.G., Gralla, R.J., Grunberg, S.M., Palmer, R., and Fitts, D.: “Antiemetic Efficacy and Safety of Different Doses of Granisetron in Patients Receiving Platinum,” Support. Care Cancer 5:31; 1997.
  • KAPLAN, H.G., and Doolittle, C.: “Hodgkin’s Disease Presenting as Steroid-Dependent Pancytopenia,” Cancer 45:3114; 1980.
  • KAPLAN, H.G.: “Inhibition of Buttermilk Xanthine Oxidase by Folate Analogues And Derivatives,” Biochem. Pharmacol. 29:2135; 1980.
  • Fefer, A., Cheever, M.A., Thomas, E.D., Appelbaum, F.R., Buckner, C.D., Clift, R.A., Glucksberg, H., Greenberg, P.D., Johnson, F.L., KAPLAN, H.G., Sanders, J.E., and Storb, R.: “Bone Marrow Transplantation for Refractory Acute Leukemia in 34 Patients with Identical Twins,” Blood 57:421; 1981.
  • Larson, S.M., Weiden, P.L., Grunbaum, Z., Rasey, J.S., KAPLAN, H.G., Graham, M.M., Harp, G., Sale, G.E., and Williams, D.L.: “Positron Imaging Feasibility Studies I: Characteristics of 3H-Thymidine Uptake in Rodent and Canine Neoplasms,” J. Nucl. Med. 22:875; 1981.
  • Larson, S.M., Weiden, P.L., Grunbaum, Z., KAPLAN, H.G., Rasey, J.S., Graham, M.M., Sale, G.E., Harp, G., and Williams, D.L.: “Positron Imaging Feasibility Studies II: Characteristics of 2-Deoxyglucose Uptake in Rodent and CanineNeoplasms,” J. Nucl. Med. 22:881; 1981.
  • Appelbaum, F.R., Fefer, A., Cheever, M.A., Buckner, C.D., Greenberg, P.D., KAPLAN, H.G., Storb, R., and Thomas, E.D.: “Treatment of Non-Hodgkin’s Lymphoma with Marrow Transplantation in Identical Twins,” Blood 58:509; 1981.
  • Fefer, A., Cheever, M.A., Greenberg, P.D., Appelbaum, F.R., Boyd, C.N., Buckner,C.D., KAPLAN, H.G., Ramberg, R., Sanders, J.E., Storb, R., and Thomas, E.D.: “Treatment of Chronic Granulocytic Leukemia with Chemoradiotherapy and Transplantation of Marrow from Identical Twins.” New England J. Med. 306:63; 1982.
  • KAPLAN, H.G., Appelbaum, F.R., Cheever, M.A., Greenberg, P.D., Wood, T., and Fefer, A.: “Treatment of Refractory Acute Non-Lymphocytic Leukemia with a Combination of Pyrazofuran and Cytosine Arabinoside,” Cancer Treat. Rep.66:1397; 1982.
  • Wiemann, M.C., Cummings, F.J., KAPLAN, H.G., Spermuli, E.N., Doolittle, C.H.,and Calabresi, P.: “Clinical and Pharmacological Studies of Methotrexate-Minimal Leucovorin Rescue Plus 5-Fluorouracil,” Cancer Res. 42:3896; 1982.
  • Larson, E.B., Scott, D.H., and KAPLAN, H.G.: “Inadequate Medical Order Writing –A Source of Confusion and Increased Costs,” Western J. Med. 139:50; 1983.
  • KAPLAN, H.G.: “Cancer Chemotherapy in the Elderly,” in Vestal, R., ed., Drug Therapy in the Elderly, Addis Press, Auckland, 1984, pp. 338-350.
  • Miller, D.R., and KAPLAN, H.G.: “Reduced NBT Dye Reduction in Phagocytes Of Patients Receiving Prednisone,” Pediatrics 45:861; 1970.
  • Friedman, J, KAPLAN, H., and Hall, J.: “The Jeune Syndrome (Asphyxiating Thoracic Dystrophy) in an Adult,” Amer. J. Med. 59:875; 1975.
  • KAPLAN, H.G., and Myers, C.E.: “Complex Inhibition of Thymidylate Synthetase By Aromatic Diamidines: Evidence for Both Rapid, Freely Reversible and Slowly Progressive Non-Equilibrium Inhibition,” J. Pharm. Exptl. Therap. 201:554; 1977.
  • Stoller, R.G., KAPLAN, H.G., Cummings, F.J., and Calabresi, P.: “A Clinical and Pharmacological Study of High-Dose Methotrexate with Minimal Leucovorin Rescue,” Cancer Res. 39:908; 1979.
  • Cummings, F.J., Stoller, R.G., KAPLAN, H.G., and Calabresi, P.: “A Clinical Study of Pyrazofuran,” Cancer Treat. Rep. 63:1363; 1979.
  • KAPLAN, H.G., Bakken, J., Quadracci, L., and Schubach, W.: “Hepatitis Caused by Repeated Sniffing of Halothane,” Annals Int. Med. 97:797; 1979.